Fedha

Hisa unazofuatilia
4502:TYO
Takeda Pharmaceutical Co Ltd
JP¥ 5,739.00
-1.53%
(-89.00) Siku 1
29 Sep, 15:30:00 GMT +9  ·   JPY
Alama zote
AlamaBeiTofautiTofauti ya asilimia
Inatayarisha maarifa maarufu ya 4502...
Fungua
JP¥ 5,861
Juu
JP¥ 5,868
Chini
JP¥ 5,722
Mtaji wa soko
9.19T
Wastani wa kiasi cha mauzo
4.11M
Kiasi cha mauzo ya hisa
4.84M
Gawio
3.48%
Mgawo wa faida wa kila robo mwaka
JP¥ 50
Tarehe ya kutojumuisha gawio
29 Sep 2026
Juu kwa wiki 52
JP¥ 6,033
Chini kwa wiki 52
JP¥ 4,102
EPS
-JP¥ 103
Hisa za wawekezaji
784.48M
Idadi ya wafanyakazi
elfu 47
Fungua
JP¥ 5,861
Juu
JP¥ 5,868
Chini
JP¥ 5,722
Mtaji wa soko
9.19T
Wastani wa kiasi cha mauzo
4.11M
Kiasi cha mauzo ya hisa
4.84M
Gawio
3.48%
Mgawo wa faida wa kila robo mwaka
JP¥ 50
Tarehe ya kutojumuisha gawio
29 Sep 2026
Juu kwa wiki 52
JP¥ 6,033
Chini kwa wiki 52
JP¥ 4,102
EPS
-JP¥ 103
Hisa za wawekezaji
784.48M
Idadi ya wafanyakazi
elfu 47
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Wasifu
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. In 2026, Julie Kim was noted in a news item as "CEO-elect". Wikipedia
Kuhusu Takeda Pharmaceutical Co Ltd
Afisa Mkuu Mtendaji (CEO)Christophe Weber | Christophe Weber
Wafanyakazielfu 47
Lilianzishwa12 Jun 1781
Makao makuu-
Sekta-
Ripoti ya mwisho
30 Jul 2026
Kipindi cha Kifedha
Robo1 2027
Mapato kwa kila hisa dhidi ya makadirio (JPY)
- / -
Mapato dhidi ya makadirio (JPY)
1.22T / 1.15T
Mkutano pepe wa kujadili mapato ya robo ya Robo ya 1 ya mwaka wa fedha wa 2027
Inasubiri mkutano pepe wa kujadili mapato
Kwa muhtasari
Maarifa kutoka kwenye ripoti na habari za hivi punde
Ripoti za awaliThamani zote katika JPY
Loading Previous Earnings...
Mapato
Mapato halisi
Thamani zote katika JPY
Sep 2025
Des 2025
Mac 2026
Jun 2026
Mapato
1.11T
1.19T
1.09T
1.22T
Gharama ya bidhaa zilizouzwa
380.06B
401.15B
453.33B
406.68B
Gharama ya mapato
380.06B
401.15B
453.33B
406.68B
Gharama za utafiti na maendeleo
161.48B
175.23B
187.96B
167.40B
Jumla ya gharama za utafiti na maendeleo
-
-
-
-
Gharama za uuzaji, za jumla na za usimamizi
253.55B
282.78B
291.96B
286.51B
Gharama ya uendeshaji
562.57B
661.30B
519.65B
612.60B
Jumla ya gharama za uendeshaji
942.63B
1.06T
972.98B
1.02T
Mapato ya uendeshaji
170.17B
129.25B
121.56B
200.62B
Mapato mengine yasiyo ya uendeshaji
77.96B
-197.22B
181.53B
-28.14B
EBT ikijumuisha vipengee visivyo vya kawaida
28.17B
133.86B
-455.02B
162.72B
EBT bila kujumuisha vipengee visivyo vya kawaida
128.86B
114.17B
71.49B
161.92B
Gharama ya kodi ya mapato
39.90B
30.13B
-86.62B
49.46B
Kiwango cha kodi kinachotumika
141.64%
22.51%
19.04%
30.40%
Gharama nyingine za uendeshaji
16.12B
67.13B
-64.27B
53.17B
Mapato halisi
-11.80B
103.64B
-368.47B
113.20B
Kiwango cha faida halisi
-1.06%
8.70%
-33.66%
9.28%
Mapato kwa kila hisa
-
-
-
-
Mapato ya riba na uwekezaji
43.92B
181.35B
-
24.61B
Gharama ya riba
-161.10B
-
-239.63B
-35.70B
Jumla ya gharama halisi za riba
-117.18B
181.35B
-239.63B
-11.09B
Gharama za kushuka kwa thamani na za kulipa deni
-
-
-
-
Mapato ya kampuni kabla ya riba, kodi, kushuka thamani na kulipa madeni
355.15B
319.89B
192.73B
363.66B
Faida au hasara kutokana na uuzaji wa vipengee
303.00M
358.00M
1.46B
-6.00B
Maudhui yaliyotayarishwa kwa AI yanaweza kuwa na makosa. Pata maelezo zaidi
Programu za Google